Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2006 1
2012 1
2017 2
2018 3
2019 6
2020 22
2021 46
2022 34
2023 26
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D; ELIPSE HoFH Investigators. Raal FJ, et al. N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215. N Engl J Med. 2020. PMID: 32813947 Clinical Trial.
Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with hom …
Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against athero …
Familial Hypercholesterolemia: Genes and Beyond.
Warden BA, Fazio S, Shapiro MD. Warden BA, et al. 2021 Oct 23. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2021 Oct 23. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 26844336 Free Books & Documents. Review.
Novel therapeutics recently developed, include: inclisiran - a small interfering ribonucleic acid (siRNA)-based gene-silencing technology that inhibits PCSK9 production (approved in the European Union only thus far), bempedoic acid - an inhibitor of adenosine triphosphate (ATP)-c …
Novel therapeutics recently developed, include: inclisiran - a small interfering ribonucleic acid (siRNA)-based gene-silencing technology th …
Hypertriglyceridaemia: an update.
Wierzbicki AS, Kim EJ, Esan O, Ramachandran R. Wierzbicki AS, et al. J Clin Pathol. 2022 Dec;75(12):798-806. doi: 10.1136/jclinpath-2021-207719. Epub 2022 Jun 16. J Clin Pathol. 2022. PMID: 35710321 Review.
Novel medications for orphan disease indications such as familial chylomicronaemia syndrome include volanesorsen, evinacumab and other antisense therapeutics. Extreme hypertriglyceridaemia syndromes, especially chylomicronaemia syndromes, which can be exposed by pregnancy …
Novel medications for orphan disease indications such as familial chylomicronaemia syndrome include volanesorsen, evinacumab and othe …
Antibodies to watch in 2022.
Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Kaplon H, et al. MAbs. 2022 Jan-Dec;14(1):2014296. doi: 10.1080/19420862.2021.2014296. MAbs. 2022. PMID: 35030985 Free PMC article. Review.
As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the United States or European Union in 2021 (evinacumab, dostarlimab loncastuximab tesirine, amivantamab, aducanumab, tralokinumab, anifrolumab, bimekizumab, tisotumab vedotin, …
As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the United States or European Union in 2021 …
Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I, Schwarz J, Berthold HK. Gouni-Berthold I, et al. Curr Atheroscler Rep. 2023 Oct;25(10):701-709. doi: 10.1007/s11883-023-01140-z. Epub 2023 Aug 29. Curr Atheroscler Rep. 2023. PMID: 37642858 Free PMC article. Review.
The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen. The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. ...
The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen. The ASO targeting APOC3, volanesorsen, is …
Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.
Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, Khilla N, McGinniss J, Gaudet D, Pordy R. Rosenson RS, et al. JAMA Cardiol. 2023 Nov 1;8(11):1070-1076. doi: 10.1001/jamacardio.2023.2921. JAMA Cardiol. 2023. PMID: 37703006 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included a 2-week screening period followed by a 16-week double-blind treatment period ( …
OBJECTIVE: To evaluate longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. DESIGN, SETTIN …
Cholesterol Lowering Drugs.
Feingold KR. Feingold KR. 2024 Feb 12. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2024 Feb 12. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 27809434 Free Books & Documents. Review.
Bempedoic acid is associated with elevations in uric acid levels and gouty attacks. Lomitapide and evinacumab are approved for lowering LDL levels in patients with homozygous familiar hypercholesterolemia, as they are not dependent on LDL receptors for decreasing LDL level …
Bempedoic acid is associated with elevations in uric acid levels and gouty attacks. Lomitapide and evinacumab are approved for loweri …
Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L, Kayikcioglu M. Tokgozoglu L, et al. Curr Cardiol Rep. 2021 Sep 4;23(10):151. doi: 10.1007/s11886-021-01565-5. Curr Cardiol Rep. 2021. PMID: 34480646 Review.
Additionally, novel agents bempedoic acid, inclisiran, and evinacumab expanded the treatment choices for some patients with FH. ...
Additionally, novel agents bempedoic acid, inclisiran, and evinacumab expanded the treatment choices for some patients with FH. ...
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K, Ginsberg HN, Choi SH. Kim K, et al. Diabetes Metab J. 2022 Jul;46(4):517-532. doi: 10.4093/dmj.2022.0198. Epub 2022 Jul 27. Diabetes Metab J. 2022. PMID: 35929170 Free PMC article. Review.
High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. ...
High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-l …
Lipid Lowering Therapy: An Era Beyond Statins.
Abdul-Rahman T, Bukhari SMA, Herrera EC, Awuah WA, Lawrence J, de Andrade H, Patel N, Shah R, Shaikh R, Capriles CAA, Ulusan S, Ahmad S, Corriero AC, Mares AC, Goel A, Hajra A, Bandyopadhyay D, Gupta R. Abdul-Rahman T, et al. Curr Probl Cardiol. 2022 Dec;47(12):101342. doi: 10.1016/j.cpcardiol.2022.101342. Epub 2022 Jul 31. Curr Probl Cardiol. 2022. PMID: 35918009 Review.
These drugs include Bile acids sequestrants, Fibrates, Nicotinic acid, Ezetimibe, Bempedoic acid, Volanesoren, Evinacumab, and the PCSK 9 Inhibitors Evolocumab and Alirocumab. Emerging gene-based therapy includes Small interfering RNAs, Antisense oligonucleotides, Adeno-as …
These drugs include Bile acids sequestrants, Fibrates, Nicotinic acid, Ezetimibe, Bempedoic acid, Volanesoren, Evinacumab, and the PC …
140 results